PCVX Stock-Based Compensation
Vaxcyte Inc · Stock-Based Compensation
PCVX Stock-Based Compensation
Latest reported$79.21Mperiod ending
PCVX Quarterly Stock-Based Comp ($266.00K → $79.21M)
Quarterly stock-based compensation
High-resolution chart · PNG
PCVX stock-based compensation history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 79,205,000 | |
| 37,964,000 | |
| 35,997,000 | |
| 35,306,000 | |
| 36,927,000 | |
| 30,615,000 | |
| 24,370,000 | |
| 21,265,000 | |
| 21,558,000 | |
| 17,629,000 | |
| 13,348,000 | |
| 13,220,000 | |
| 12,544,000 | |
| 9,648,000 | |
| 7,009,000 | |
| 6,648,000 | |
| 5,894,000 | |
| 4,099,000 | |
| 3,158,000 | |
| 2,937,000 | |
| 2,769,000 | |
| 1,865,000 | |
| 1,935,000 | |
| 1,838,000 | |
| 1,289,000 | |
| 372,000 | |
| 375,000 | |
| 265,000 | |
| 279,000 | |
| 266,000 |